Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arvinas, Inc. - Common Stock (NQ: ARVN )

18.73 +0.73 (+4.06%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 449,360
Open 18.06
Bid (Size) 18.00 (5)
Ask (Size) 23.00 (3)
Prev. Close 18.00
Today's Range 17.81 - 18.75
52wk Range 17.37 - 53.08
Shares Outstanding 68,700,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Demystifying Arvinas: Insights From 5 Analyst Reviews
Via Benzinga
Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients
Arvinas and Pfizer share Phase 1b TACTIVE-U trial results showing 62.5% clinical benefit rate and tolerable safety for advanced breast cancer therapy. 
Via Benzinga

Performance

YTD
-54.87%
-54.87%
1 Month
-25.53%
-25.53%
3 Month
-24.26%
-24.26%
6 Month
-23.43%
-23.43%
1 Year
-54.42%
-54.42%

More News

Read More
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference
From Arvinas Inc.
Via GlobeNewswire
Unveiling 4 Analyst Insights On Arvinas
Via Benzinga
What's Next: Arvinas's Earnings Preview
Via Benzinga
Critical Insights From Arvinas Analyst Ratings: What You Need To Know
Via Benzinga
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
The Latest Analyst Ratings For Arvinas
Via Benzinga
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
ARVN Stock Earnings: Arvinas Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Biotech Arvinas Stock Earns 82 RS Rating
Via Investor's Business Daily
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
From Arvinas Inc.
Via GlobeNewswire
These 3 Clinical-Stage Biotech Stocks Can Offer Exponential Gains
Via Talk Markets
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.